

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims: Please amend the claims as follows:

We claim:

Claims 1.-29. (Cancelled)

Claim 30. (New) A pharmaceutical composition comprising a first antibody molecule or a portion thereof and a second antibody molecule or a portion thereof, having the capability to bind to different epitopes located on an ErbB1 receptor molecule, wherein said first antibody molecule or a portion thereof comprises a binding site that bind to a first specific epitope on the ErbB1 receptor molecule, and said second antibody molecule comprises a binding site that binds to a second specific different epitope on said ErbB1 receptor molecule,

wherein said first and said second epitopes on the ErbB1 receptor molecule are located within the ErbB1 receptor ligand-binding domain, thereby increasing the amount of antibody bound per receptor and per cell by the same antibody dose and causing an enhanced ErbB1 blocking and/or inhibition and induction of down-regulation of ErbB1 receptor-specific pathway signaling as compared with a composition comprising said first or second antibody molecule only,

wherein said first antibody is murine, chimeric, or humanized MAb 425 or murine, chimeric, or humanized MAb 225.

Claim 31. (New) The pharmaceutical composition according to claim 30, wherein, the first antibody is murine, chimeric or humanized MAb 425, and the second antibody is murine, chimeric or humanized MAb 225.

Claim 32. (New) The pharmaceutical composition according to claim 31, wherein said first antibody is humanized MAb 425 (h425) and said second antibody is chimeric MAb 225 (c225).

Claim 33. (New) The pharmaceutical composition according to claim 30,

wherein said receptor ligand-binding domain is the binding domain of the natural ligand of said ErbB1 receptor.

Claim 34. (New) The pharmaceutical composition according to claim 30, wherein said composition exhibits enhanced induction of cross-linking and/or dimerization of ErbB1 receptor molecule compared to a composition comprising a single antibody molecule which binds to said first or said second epitope on said ErbB1 receptor molecule.

Claim 35. (New) The pharmaceutical composition according to claim 30, further comprising a cytotoxic agent.

Claim 36. (New) The pharmaceutical composition according to claim 35, wherein said cytotoxic agent is a chemotherapeutic agent.

Claim 37. (New) The pharmaceutical composition according of claim 36, wherein said chemotherapeutic agent is cisplatin, doxorubicin, gemcitabine, docetaxel, paclitaxel, or bleomycin.

Claim 38. (New) The pharmaceutical composition according of claim 35, wherein said cytotoxic agent is an ErbB receptor inhibitor, a VEGF receptor inhibitor, a tyrosine kinase inhibitor, a protein kinase A inhibitor, an anti-angiogenic agent, or a cytokine.

Claim 39. (New) A kit comprising the pharmaceutical composition of claim 30 in one package and a carrier in a second package.

Claim 40. (New) A method of inhibiting tumor growth and/or metastasis comprising contacting said tumor with the pharmaceutical composition according of claim 30.